English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/125938
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations

AutorMatos, Liliana; Desviat, Lourdes R. ; Pérez, Belén ; Vilageliu, Lluïsa
Palabras claveSplicing mutations
Modified U1 snRNAs
Sanfilippo C syndrome
Lysosomal storage disorder
Fecha de publicación10-dic-2014
EditorBioMed Central
CitaciónOrphanet Journal of Rare Diseases 9(1):180 (2014)
Resumen[Background] Mutations affecting RNA splicing represent more than 20% of the mutant alleles in Sanfilippo syndrome type C, a rare lysosomal storage disorder that causes severe neurodegeneration. Many of these mutations are localized in the conserved donor or acceptor splice sites, while few are found in the nearby nucleotides.
[Methods] In this study we tested several therapeutic approaches specifically designed for different splicing mutations depending on how the mutations affect mRNA processing. For three mutations that affect the donor site (c.234 + 1G > A, c.633 + 1G > A and c.1542 + 4dupA), different modified U1 snRNAs recognizing the mutated donor sites, have been developed in an attempt to rescue the normal splicing process. For another mutation that affects an acceptor splice site (c.372-2A > G) and gives rise to a protein lacking four amino acids, a competitive inhibitor of the HGSNAT protein, glucosamine, was tested as a pharmacological chaperone to correct the aberrant folding and to restore the normal trafficking of the protein to the lysosome.
[Results] Partial correction of c.234 + 1G > A mutation was achieved with a modified U1 snRNA that completely matches the splice donor site suggesting that these molecules may have a therapeutic potential for some splicing mutations. Furthermore, the importance of the splice site sequence context is highlighted as a key factor in the success of this type of therapy. Additionally, glucosamine treatment resulted in an increase in the enzymatic activity, indicating a partial recovery of the correct folding.
[Conclusions] We have assayed two therapeutic strategies for different splicing mutations with promising results for the future applications.
DescripciónMatos, Liliana et al.
Versión del editorhttp://dx.doi.org/10.1186/s13023-014-0180-y
Aparece en las colecciones: (CBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
13023_2014_Article_180.pdf1,38 MBAdobe PDFVista previa
Mostrar el registro completo

Artículos relacionados:

NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.